ALBERT DAVIDAlbert David Ltd. is a pharmaceutical company engaged in the manufacturing and marketing of formulations, bulk drugs, and healthcare solutions. It serves domestic and export markets with products across therapeutic areas such as gastroenterology, gynecology, and general medicine. The stock is currently trading at INR 881.55, showing signs of upward momentum following a period of consolidation.
Key Levels
Support Levels: INR 758.00, INR 970.50, INR 1,141.30
Swing Level: INR 881.55
Possible Upside: INR 1,545.65, INR 1,758.55, INR 2,027.70
Technical Indicators
RSI (Relative Strength Index): Currently at 46.17, suggesting neutral momentum. A break above the mid-50s range would confirm growing strength.
Volume: At 21.34K, the rising volume alongside recent price uptick signals early signs of accumulation and potential trend development.
Sector and Market Outlook
Albert David operates in India’s formulation-driven pharmaceutical sector, which is buoyed by:
Consistent domestic demand for generics and branded formulations
Increased R&D investments for differentiated dosage forms and APIs
Evolving export strategy amid global interest in Indian pharma suppliers
Challenges include pricing caps by regulators, raw material import reliance (especially for APIs), and generic competition from larger incumbents.
Latest Developments
Manufacturing Upgrade: Recent investments in facility modernization to meet evolving GMP standards
Product Portfolio Expansion: Strengthening presence in anti-infectives and critical care segments
Earnings Performance: Sequential growth in operating margins with a focus on efficiency and therapeutic diversification
Dividend Update
Albert David Ltd. has maintained a consistent payout strategy, most recently declaring a dividend of ₹5.00 per share, reflecting stable fundamentals and shareholder alignment.
Analysis Summary
Albert David Ltd. is exhibiting a technically constructive setup within the broader pharma space. While momentum remains neutral, increasing volume and structural stability support a positive outlook. With improving fundamentals and rising investor participation, the stock may be entering a base-building phase with scope for medium-term trend development as sector sentiment strengthens.
